Management of Early-Stage Breast Cancer: Reducing the Risk for Recurrence

Tarah J. Ballinger, MD


August 01, 2022

Tarah J. Ballinger, MD, considers the plight of patients with triple-negative breast cancer, who frequently experience recurrence of their cancer as a consequence of residual disease.

But there is light on the horizon, Dr Ballinger counsels. New diagnostic and monitoring innovations such as circulating tumor DNA (ctDNA), which offer more prompt assessment of disease status, are poised to enter the early breast cancer space, permitting clinicians to assemble more targeted therapeutic strategies that will improve patient outcomes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.